Skip to main content
B

BUKWANG PHARMACEUTICAL IND CO.,LTD — Investor Relations & Filings

Ticker · 003000 ISIN · KR7003000007 KO Manufacturing
Open in API
Filings indexed 322 across all filing types
Latest filing 2026-04-27 M&A Activity
Country KR South Korea
Listing KO 003000

About BUKWANG PHARMACEUTICAL IND CO.,LTD

https://www.bukwang.co.kr/en/

Bukwang Pharmaceutical is a research and development-focused company that develops, produces, and sells a range of pharmaceutical and oral hygienic products. The company emphasizes an open innovation strategy, leveraging joint ventures, research collaborations, and strategic investments to build a robust drug pipeline. Its key development areas include treatments for central nervous system disorders like schizophrenia, bipolar depression, and dyskinesia in Parkinson's disease. The pipeline also features oncology candidates, such as a treatment for metastatic prostate cancer. Bukwang Pharmaceutical manufactures various dosage forms, including oral solids and injections, alongside over-the-counter medications.

Recent filings

Filing Released Lang Actions
타법인주식및출자증권취득결정
M&A Activity Classification · 1% confidence The document is a regulatory disclosure detailing a board resolution to acquire 60,000,000 shares (74.97%) of another company via third-party allotment, including acquisition price, purpose, method, timeline, and financial summaries of the target. This constitutes an M&A/takeover announcement rather than an earnings release or financing update. Therefore it fits the M&A Activity category (TAR).
2026-04-27 Korean
연결재무제표기준영업(잠정)실적(공정공시)
Earnings Release Classification · 1% confidence The document is a brief public disclosure (“공정공시”) of preliminary consolidated financial results for Q1 2026, showing key figures (sales, operating profit, net profit) vs. prior periods. It constitutes an initial earnings announcement of quarterly results rather than a full interim report or annual report. Therefore, it fits the “Earnings Release (ER)” category. Q1 2026
2026-04-21 Korean
기업설명회(IR)개최(안내공시)
Investor Presentation Classification · 1% confidence The document announces the scheduling and details of an investor presentation (IR) event, including date, time, participants, purpose (to explain Q1 results and R&D status), and how to attend via conference call. This aligns exactly with an Investor Presentation announcement, not a full report or earnings release. Therefore, it should be classified under Investor Presentation (IP).
2026-04-15 Korean
정기주주총회결과
Declaration of Voting Results & Voting Rights Announcements Classification · 1% confidence The document is a post-AGM announcement showing the results of resolutions passed at the regular shareholders’ meeting: approval of financial statements, dividend resolutions, election/remuneration matters, and vote tallies. This fits the Definition for Declaration of Voting Results (DVA).
2026-03-24 Korean
기업가치제고계획(자율공시)
Capital/Financing Update Classification · 1% confidence The document is a voluntary corporate disclosure (“자율공시”) detailing the company’s ‘기업가치 제고 계획’ (corporate value enhancement plan), specifically outlining its dividend policy and shareholder return strategy. It is not an annual or quarterly report, nor a governance or legal update. It provides an update on the company’s planned capital allocation (dividend policy) and thus best fits under Capital/Financing Update (CAP).
2026-03-24 Korean
사업보고서 (2025.12)
Annual Report Classification · 1% confidence The document is a 'Business Report' (사업보고서) for Bukwang Pharm Co., Ltd. for the fiscal year 2025 (Jan 1, 2025 to Dec 31, 2025). It contains comprehensive financial statements, management discussion and analysis, governance information, and auditor reports, which are the standard components of a 10-K equivalent filing in the South Korean regulatory system (DART). FY 2025
2026-03-16 Korean

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.